The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2026 | Higher BMI linked to improved survival in GI cancer patients receiving immunotherapy
Kushal Kriplani, MBBS, SUNY Downstate Health Sciences University, Brooklyn, NY, discusses the obesity paradox in patients with gastrointestinal cancer receiving immunotherapy, highlighting findings from a retrospective multi-institutional US cohort study showing that patients with higher BMI tend to have better outcomes, with approximately double the overall survival (OS) compared to those with normal BMI. Dr Kriplani notes that this finding is observational and that the hypothesis needs to be further tested. This interview took place during the 2026 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
